It seems the magic potion that kept Madeline and Helen eternally youthful in Death Becomes Her couldn't quite extend the life of its Broadway run. The campy musical, based on the beloved 1992 film, is set to close its curtains on June 28th, after a run of just under two years and 650 performances. Personally, I find this closure a bit disheartening, not just for the show itself, but for what it might signal about the current landscape of Broadway productions.
The Price of Immortality (and Spectacle)
What makes this closure particularly striking is the financial reality. The production reportedly failed to recoup its massive $31.5 million investment. This isn't a minor detail; it speaks volumes about the immense financial risks involved in mounting a Broadway show, especially one that leans heavily into special effects, as Death Becomes Her undoubtedly did. In my opinion, the sheer cost of bringing such elaborate visions to life on stage is becoming an ever-increasing hurdle for new musicals. It's fascinating to note that only a handful of shows have managed to turn a profit since the pandemic, and Death Becomes Her isn't among them. This raises a deeper question: are we reaching a point where only the most universally appealing, or perhaps the most cost-effective, new musicals can realistically aim for profitability on Broadway?
A Celebration of Camp and Comedy
Despite the financial outcome, the critical reception for Death Becomes Her was largely positive, and the performances by Megan Hilty and Jennifer Simard, who stepped into the iconic roles originated by Meryl Streep and Goldie Hawn, were clearly a highlight. Their Tony nominations for these comedic turns are a testament to their talent and the show's ability to capture that specific brand of dark, surreal humor. What I find especially interesting is how the show managed to garner 10 Tony Award nominations, the most for the season, yet only secured one win for costume design. This suggests a show that was admired for its ambition and execution in certain areas, but perhaps didn't quite capture the hearts of the Tony voters across the board. It's a common narrative for shows that are perhaps a bit too niche or too avant-garde to gain widespread critical acclaim.
The Road Ahead: A Tour of Hope?
However, all is not lost for the undead duo. The silver lining, and a crucial one for recouping costs, is the upcoming North American tour set to launch in September. From my perspective, this tour represents a significant opportunity for Death Becomes Her to find a broader audience and, hopefully, a more sustainable financial footing. Broadway is a unique, high-stakes environment, and what might not thrive in its intense spotlight can often find a very appreciative home on the road. It's a classic strategy, but one that can truly make or break a show's legacy. What this really suggests is that the spirit of Death Becomes Her is resilient, and its journey is far from over. I'm eager to see how it performs in different markets and whether its unique brand of dark comedy and spectacle will resonate more widely outside the Big Apple.
Ultimately, the story of Death Becomes Her on Broadway is a poignant reminder of the delicate balance between artistic vision, financial viability, and audience reception in the theater world. It's a reminder that even with critical praise and multiple nominations, the path to Broadway success is a treacherous one. But the promise of a national tour offers a compelling narrative of hope and continued life for this particular theatrical endeavor.
